

1 **Cardiac Inflammation after COVID-19 mRNA Vaccines:**  
2 **A Global Pharmacovigilance Analysis**

3 **Brief title:** Cardiac Inflammation after COVID-19 Vaccines

4  
5 Laurent Chouchana PharmD, PhD <sup>1\*¶</sup>, Alice Blet MD, PhD <sup>2,3,4\*</sup>, Mohammad Al-Khalaf PhD <sup>2</sup>,  
6 Tahir S. Kafil, MD <sup>2</sup>, Girish Nair, MD <sup>2</sup>, James Robblee, MD <sup>2</sup>, Milou-Daniel Drici, MD, PhD <sup>5¶</sup>,  
7 Marie-Blanche Valnet-Rabier, PharmD, PhD <sup>6¶</sup>, Joëlle Micallef, MD, PhD <sup>7¶</sup>, Francesco Salvo,  
8 MD, PhD <sup>8,9¶</sup>, Jean-Marc Treluyer, MD, PhD <sup>1,10¶</sup> and Peter P. Liu MD <sup>2</sup>

9  
10 <sup>1</sup> Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP.Centre –  
11 Université de Paris, Paris, France.

12 <sup>2</sup> University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L.,  
13 M.A.K), University of Ottawa, Ontario, Canada.

14 <sup>3</sup> Department of Anesthesiology, Critical Care and Burn Center, Lariboisière - Saint-Louis Hospitals, DMU  
15 Parabol, AP-HP Nord, University of Paris, France.

16 <sup>4</sup> Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, France.

17 <sup>5</sup> Regional Center of Pharmacovigilance, Department of Pharmacology, Nice University Hospital, Nice, France

18 <sup>6</sup> Regional Center of Pharmacovigilance, Department of Pharmacology, Besançon University Hospital, Besançon,  
19 France

20 <sup>7</sup> UMR 1106, Institute of Neurosciences System, Aix-Marseille University, Inserm, Marseille, France. Regional  
21 center of Pharmacovigilance, Department of Clinical Pharmacology and Pharmacovigilance, University Hospitals  
22 of Marseille, Marseille, France.

23 <sup>8</sup> Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France

24 <sup>9</sup> CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie médicale, Centre Régional de  
25 Pharmacovigilance, Bordeaux<sup>10</sup> University of Paris, Paris, France.

26  
27 \* LC and AB share first position authorship.

28 ¶ Laurent Chouchana, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo and  
29 Jean-Marc Treluyer are members of the French Pharmacovigilance Network.

30  
31 **Address for correspondence:** Dr. Peter Liu

32 [peter.liu@utoronto.ca](mailto:peter.liu@utoronto.ca) OR [pliu@ottawaheart.ca](mailto:pliu@ottawaheart.ca)

33 Phone: +1 613 696 7000 x 19544 / Fax: +1 613 696 7138

34 University of Ottawa Heart Institute

35 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

36

37 **Sources of funding:** This work is supported in part by research grants from the Canadian  
38 Institutes of Health Research, Heart & Stroke Foundation of Canada, Genome Canada, and  
39 University of Ottawa of Heart Institute.

40

41 **Disclosures:** none

42

43 **Total word count:** 6910                      Number of figures: 5                      Number of tables: 2

44

45

46

47

48 **ABSTRACT**

49 *Background*

50 To counter the COVID-19 pandemic, mRNA vaccines, namely tozinameran and  
51 elasomeran, have been authorized in several countries. These next generation vaccines have  
52 shown high efficacy against COVID-19 and demonstrated a favorable safety profile. As  
53 widespread vaccinations efforts are taking place, incidents of myocarditis and pericarditis cases  
54 following vaccination have been reported. This safety signal has been recently confirmed by the  
55 European Medicine Agency and the U.S. Food and Drug Administration.

56 This study aimed to investigate and analyze this safety signal using a dual  
57 pharmacovigilance database analysis.

58 *Methods*

59 This is as an observational study of reports of inflammatory heart reactions associated  
60 with mRNA COVID-19 vaccines reported in the World Health Organization's global individual  
61 case safety report database (up to June 30<sup>th</sup> 2021), and in the U.S. Vaccine Adverse Event  
62 Reporting System (VAERS, up to May 21<sup>st</sup> 2021). Cases were described, and disproportionality  
63 analyses using reporting odds-ratios (ROR) and their 95% confidence interval (95%CI) were  
64 performed to assess relative risk of reporting according to patient sex and age.

65 *Results*

66 At a global scale, the inflammatory heart reactions most frequently reported were  
67 myocarditis (1241, 55%) and pericarditis (851, 37%), the majority requiring hospitalization  
68 (n=796 (64%)). Overall, patients were young (median age 33 [21-54] years). The main age group  
69 was 18-29 years old (704, 31%), and mostly males (1555, 68%). Pericarditis onset was delayed  
70 compared to myocarditis with a median time to onset of 8 [3-21] vs. 3 [2-6] days, respectively  
71 (p=0.001). Regarding myocarditis, an important disproportionate reporting in males (ROR, 9.4

72 [8.3-10.6]) as well as in adolescents (ROR, 22.3 [19.2-25.9]) and 18-29 years old (ROR, 6.6 [5.9-  
73 7.5]) compared to older patients were observed.

#### 74 *Conclusions*

75 The inflammatory heart reactions, namely myocarditis and pericarditis, have been  
76 reported world-wide shortly following COVID-19 mRNA vaccination. An important  
77 disproportionate reporting among adolescents and young adults, particularly in males, was  
78 observed especially for myocarditis. Guidelines must take this specific risk into account and to  
79 optimize vaccination protocols according to sex and age. While the substantial benefits of  
80 COVID-19 vaccination still prevail over risks, clinicians and the public should be aware of these  
81 reactions and seek appropriate medical attention.

82

#### 83 **Key words**

84 mRNA vaccines, myocarditis, pericarditis, adverse drug reactions, pharmacovigilance, COVID-  
85 19 vaccines

86

87 **ABBREVIATION LIST**

CDC	Centers for Disease Control and Prevention
95%CI	Confidence Interval 95%
COVID-19	coronavirus disease
FDA	U.S. Food and Drug Administration
IQR	interquartile range
MedDRA	Medical Dictionary for Regulatory Activities
mRNA	messenger RNA
OR	Odds Ratio
ROR	Reporting Odds Ratio
VAERS	Vaccine Adverse Event Reporting System
WHO	World Health Organization

88

89

90 **Introduction**

91 Myocarditis and pericarditis are inflammatory heart conditions that occur in the setting of  
92 excessive host immune response to antigenic stimuli, and have diverse outcomes ranging from  
93 mild to severe.<sup>1</sup> They usually occur after viral infections or other stimuli that induce immune  
94 system activation.<sup>2</sup> Recently, viral myocarditis has been widely reported after SARS-CoV-2  
95 infection and subsequent development of coronavirus disease (COVID-19).<sup>3,4</sup> In some instances,  
96 these inflammatory reactions have been associated with some drug exposure, such anticancer  
97 agents, clozapine or vaccines.<sup>5-7</sup> A descriptive analysis of drug associated myopericarditis  
98 spontaneous reports in the United States (1990–2018) identified that about 0.1% of the cases  
99 were related to vaccines.<sup>8</sup> To date, inflammatory cardiac reactions following vaccination have  
100 been mostly reported with live-virus vaccines, such as the smallpox vaccine,<sup>6,9,10</sup> and inactivated  
101 influenza vaccines,<sup>11</sup> Cases reports of myocarditis/pericarditis secondary to next-generation  
102 vaccine platforms, used to prevent COVID-19, have been reported.<sup>12-17</sup>

103 Vaccination is critical to contain the SARS-CoV-2 pandemic. Messenger RNA (mRNA)  
104 vaccines, which have been produced experimentally during the Zika virus outbreak, represent a  
105 new generation of vaccines that can be rapidly responsive to emerging viruses, such as SARS-  
106 CoV-2.<sup>18</sup> Pivotal phase 3 randomized clinical trials were conducted on 71,265 volunteers,  
107 including 35,654 who were exposed to the active mRNA vaccines.<sup>19,20</sup> Up to July 2021,  
108 tozinameran (BNT162b2 mRNA, Pfizer-BioNTech) and elasomeran (mRNA 1273, Moderna)  
109 have been distributed in 104 and 49 countries worldwide, respectively, and more than 341 million  
110 doses have been administered in the U.S.<sup>21</sup> While these vaccines appear to have a particularly  
111 good safety profile, special attention must be paid to potential adverse effects due to their  
112 novelty. Rare but severe adverse drug reactions have been highlighted in clinical trials and  
113 thereafter reported after COVID-19 mRNA vaccination, such as anaphylaxis or Bell's palsy.<sup>22-24</sup>

114 Recently, a growing signal concerning inflammatory heart reactions, which has not been pointed  
115 out during clinical trials, has emerged in several regions of the world, including Israel, Europa  
116 and the U.S., with early coverage in the press.<sup>25-27</sup> A small case series in members of the U.S.  
117 Military suggested an incidence below one over 100,000 doses administered.<sup>14</sup> Preliminary  
118 analysis by national authorities led to confirm this safety signal and a probable causal relationship  
119 in Europe and in the U.S.<sup>28,29</sup>

120 In this study, we aim to document the inflammatory heart reactions reported after  
121 COVID-19 mRNA vaccination and further analyze this safety signal using a dual  
122 pharmacovigilance database analysis based on the World Health Organization's (WHO) global  
123 Individual Case Safety Report database (VigiBase) and the U.S. Vaccine Adverse Event  
124 Reporting System (VAERS). The aims of the study are: 1) to describe these cases and their  
125 relevant clinical features, and 2) to perform disproportionality analyses to evaluate a potential  
126 association of inflammatory heart reactions reporting after mRNA COVID-19 vaccines with  
127 patient's sex and age.

128

129

130

## 131 **Methods**

### 132 *Study Design*

133 This is a retrospective observational study of spontaneous reports of inflammatory heart  
134 reactions associated with mRNA COVID-19 vaccines, collected from VigiBase and the VAERS.

135

### 136 *Data Source*

137           VigiBase (<https://www.who-umc.org/vigibase/vigibase/>) is the unique WHO global  
138 database of individual case safety reports (ICSRs).<sup>30</sup> This database is maintained, deduplicated  
139 and deidentified by Uppsala Monitoring Centre (Uppsala, Sweden). VigiBase is the world's  
140 largest pharmacovigilance database, with over 23 million reports of suspected adverse drug  
141 reactions gathered from national pharmacovigilance systems and continuously updated. More  
142 than 130 countries, over five continents submit spontaneous safety report in this database.  
143 Information concerning the reporter, the patient, the suspected and concomitant drugs, the  
144 suspected adverse drug reactions and their seriousness, are reported for each case. Reactions are  
145 coded using the hierarchical Medical Dictionary for Regulatory Activities (MedDRA)  
146 (<https://www.meddra.org/>).

147           VAERS ([www.vaers.hhs.gov](http://www.vaers.hhs.gov)) is the national pharmacovigilance database to monitor the  
148 safety of U.S.-licensed vaccines.<sup>31,32</sup> It is run by the Centers for Disease Control and Prevention  
149 (CDC) and the U.S. Food and Drug Administration (FDA). VAERS is a spontaneous, passive,  
150 reporting system. Health-care professionals, vaccine manufacturers, and consumers (patients,  
151 parents, and caregivers) can submit reports of suspected adverse drug reactions to VAERS. They  
152 include a short narrative with clinical and biological features on the patient medical history, the  
153 reaction and its outcome. This short narrative allows data extraction to deeper describe the  
154 reports. U.S. reports from VAERS are transmitted to VigiBase on a regular basis.

155

### 156 *Ethics*

157           This study has obtained ethics approval from the Cochin university Hospital institutional  
158 review board (number AAA-2021-08039) in conformity with the French laws and regulations.<sup>33</sup>  
159 All of the data used for analysis were de-identified, and only aggregate data are reported.

160



161 *Data Extraction and Analysis*

162 Reports including a COVID-19 mRNA vaccine (tozinameran or elasomeran) as the  
163 suspected drug in the adverse reaction have been extracted from both databases. From that, cases  
164 of inflammatory heart reactions, i.e. myocarditis, myopericarditis, pericarditis, and  
165 pleuropericarditis, were retrieved using the *ad-hoc* high-level terms from MedDRA, “non  
166 infectious myocarditis” and “non infectious pericarditis”, coded as reactions. Cases included in  
167 this study were registered up to May 21<sup>st</sup> and June 30<sup>th</sup> 2021, in VAERS and in VigiBase,  
168 respectively.

169 In VigiBase, for each report of interest, the following data were extracted or assessed:  
170 demographic features, continent of reporting, type of reporter, month of reporting, patient sex,  
171 patient age, time to reaction onset, seriousness, reaction outcome and type of heart inflammatory  
172 reaction Serious cases were defined, according to the WHO, as the occurrence of death, life-  
173 threatening adverse event, inpatient hospitalisation or prolongation of an existing hospitalisation,  
174 significant disability or requirement of intervention to prevent any of these.

175 In VAERS, for each report of interest, the following data were extracted or assessed:  
176 vaccine type, type of heart inflammatory reaction, patient age, sex, COVID-19 prior to  
177 vaccination, reaction occurrence after the 1<sup>st</sup> or 2<sup>nd</sup> dose of vaccine, onset of the symptoms, type  
178 of symptoms, biological and radiological exams, complications, treatment, and hospitalization.  
179 Duplicates in VAERS were removed when identified from the short narrative.

180

181 *Disproportionality analysis*

182 Disproportionality analyses, also called case – non-case studies are similar to case – control  
183 studies but for purpose of pharmacovigilance studies. These studies are nested in a database of  
184 spontaneous reports to assess possible disproportionality in reporting. Disproportionality analysis

185 compares the proportion of a specific adverse drug reaction reported in a specific group (e.g. drug  
186 exposure, patient age, patient sex) with the proportion of the same adverse drug reaction for a  
187 control group.<sup>34-36</sup> This statistical approach has shown its value to assess relative risks of adverse  
188 drug reaction, that are correlated in most cases with results from meta-analyses of clinical trials.<sup>37</sup>  
189 To assess an association between inflammatory heart reactions after mRNA vaccines and patient  
190 age or sex, we performed a disproportionality analysis among different patient groups.  
191 Characteristics of interest are patient sex and age groups, specially 12-17 years, 18-29 years and  
192 over 30 years, as reported by safety signals of concern. Cases are reports concerning a specific  
193 patient group and that include the terms myocarditis, pericarditis or pleuropericarditis as reactions  
194 after a COVID-19 mRNA vaccine. Non-cases are reports concerning a specific patient group and  
195 that include all other reactions to a COVID-19 mRNA vaccine. Therefore, our analyses assessed  
196 a potential difference of reporting of inflammatory heart reactions secondary to COVID-19  
197 mRNA vaccines in male compared to female and in 12-17 years or 18-29 years old patients  
198 compared to patients over 30 years old. Thereafter, sensitivity analyses were performed,  
199 restricted to serious reports only, and to reports originating from a healthcare professional.

200

### 201 *Statistical analysis*

202 Descriptive analysis was performed on the cases retrieved from the two databases. Quantitative  
203 variables were expressed as median  $\pm$  interquartile range (IQR) and compared using non-  
204 parametric analysis. Qualitative variables were expressed in number and percentages. Time to  
205 reaction onset was analyzed using a survival Mantel-Cox model.

206 Disproportionality in reporting between groups is expressed using reporting odds ratio (ROR)  
207 and its 95% confidence interval (95% CI). ROR is a ratio similar in concept to the odds ratio in  
208 case – control studies and corresponds to the exposure odds among reported cases of interest over

209 the exposure odds among reported non-cases. ROR (95% CI) were calculated as

210  $\frac{ad}{bc} (e^{\pm 1.96 \sqrt{(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d})}}$ , where  $a$  is the number of cases reported with COVID-19 mRNA

211 vaccines in a specific patient group,  $b$  is the number of non-cases (i.e., all other adverse drug

212 reactions) reported with COVID-19 mRNA vaccines in a specific patient group,  $c$  is the number

213 of cases reported with COVID-19 mRNA vaccines in a control group and  $d$  is the number of non-

214 cases reported with COVID-19 mRNA vaccines in a control group.

215

216

## 217 **Results**

### 218 *Demographics and characteristics of cases from the worldwide Vigibase*

219 As of the end of June 2021, of a total of 26,258,646 reports registered in Vigibase,

220 716,576 reports were related to a COVID-19 mRNA vaccine as a suspected drug, including

221 495,493 with tozinameran and 221,368 with elasomeran (including 285 with both vaccines).

222 Among them, 2277 cases of inflammatory heart reactions (31.8 per 10,000 of COVID-19 mRNA

223 vaccine reports) were retrieved in the worldwide Vigibase. Cases were largely reported from

224 North America (63.4%) and Europa (35.0%). Of the cases, 1655 (72.7%) were reported with

225 tozinameran and 622 (27.3%) with elasomeran (**Table 1**). The inflammatory heart reactions most

226 commonly reported were myocarditis (1241, 54.5%) and pericarditis (851, 37.4%). Patients were

227 of the younger age bracket (median age 33 [21-54]) mostly from the group between 18-29 year-

228 old (704, 30.9%), more commonly males (1555 (68.3%). Patient distribution was different

229 according to age and sex ( $p < 0.0001$ ) for both myocarditis and pericarditis (**Figure 1**).

230 Specifically, most of myocarditis cases have been reported in 12-17 and 18-29 years old males.

231 Myocarditis cases originating from the U.S. were mainly reported after May 2021, although

232 reactions occur alongside with vaccination achievements (**Figure 2A** and **suppl. figure 1**).  
233 Overall, the median time to onset was 3 [2-14] days after vaccine injection. Pericarditis onset was  
234 delayed compared to myocarditis with a median time to onset of 8 [3-21] vs. 3 [2-6] days,  
235 respectively (p=0.001, **Figure 3A**). Drug other than COVID-19 mRNA vaccines were suspected  
236 in the cardiac reaction onset in 200 (8.7%) patients. Overall, most of the myocarditis and  
237 pericarditis reported cases required hospitalization (1015 (81.8%) and 492 (57.8%), respectively),  
238 and 219 (21.5%) and 101 (20.5%) were life threatening, respectively. In 22 patients, including 15  
239 (1.2%) myocarditis cases (median age 60 [56-78] years old), 5 pericarditis cases (median age 71  
240 [67-77] years old) and 2 myopericarditis cases (age 55 and 83), the cardiac inflammatory reaction  
241 had a fatal outcome. Among these fatal cases, the vaccine was the only suspected drug in all  
242 except one case (an anti-PDL1, atezolizumab, as other suspected drug).

243

#### 244 *Disproportionality analysis*

245 Compared to females, vaccination by COVID-19 mRNA vaccines in males was  
246 associated with an increased risk of myocarditis and pericarditis reporting with an ROR (95% CI)  
247 of 9.4 (8.3-10.6) and 3.7 (3.2-4.2), respectively (**Figure 4A and B**). Analysis according to age  
248 group showed a marked disproportionate reporting of myocarditis after COVID-19 mRNA  
249 vaccines in 12-17 years old (ROR 22.3 [19.2-25.9]) and 18-29 years old (ROR 6.6 [5.9-7.5])  
250 recipients compared with recipients over 30 years old. Specifically, this increased reporting was  
251 more marked in males than in females, among all age groups (**Figure 4A**). Regarding  
252 pericarditis, a disproportionate reporting in males among all age groups, compared to females  
253 was observed (**Figure 4B**). Younger males belonging to 12-17 and 18-29 years old groups were  
254 also more prone to pericarditis reporting after COVID-19 mRNA vaccines compared to over 30  
255 years old group. This finding not being true in females in whom no disproportionality in

256 pericarditis reporting was observed according to age. Further sensitivity analyses restricted to  
257 serious reports and to reports originating from healthcare professionals identified consistent  
258 results (**Suppl tables S2, S3, S4 and S5**).

259

#### 260 *Demographic and characteristics of cases from the U.S. VAERS*

261 A total of 279 cases of inflammatory cardiac reaction with COVID-19 mRNA vaccines  
262 were reported in VAERS during the observed period. Of them, 157 (56%) myocarditis and 122  
263 (44%) pericarditis cases were reported (**Table 2, Suppl. Table 1**). Patients were young belonging  
264 to the 18-39 age group (142, 51%), more commonly males (182, 65%). Adverse reactions  
265 occurred after the 1<sup>st</sup> dose for 52 (19%), or after the 2<sup>nd</sup> dose for 87 (31%) and unspecified for  
266 140 (50%) of reported cases. COVID-19 disease prior to vaccination was reported for 18 (6%)  
267 patients. There was no concomitant COVID-19 reported. Although the median time to onset was  
268 similar for myocarditis and pericarditis, it tends to be longer for pericarditis (3 [2-4] days vs. 3 [2-  
269 9] days, respectively). Main symptoms are reported for myocarditis and pericarditis (respectively  
270 **Figure 3B and C**), with chest pain being most common. As illustrated in **Figure 5**, most cases of  
271 myocarditis experienced systemic reactogenicity signs (myalgia, fatigue, lymphedema on  
272 axillary, sweats and chills, fever, headache) appeared at day 1 (70, 45%), followed at day 3 to 4  
273 by chest pain (107, 68%) and shortness of breath (26, 17%). Electrocardiogram (ECG) was  
274 abnormal for 68 (43%) patients with myocarditis and troponin was elevated for 41 (26%). The  
275 most common drugs reported to treat these myocarditis reactions included non-steroidal anti-  
276 inflammatory drugs (NSAID) (23, 15%) and colchicine (22, 14%). Corticosteroid therapy was  
277 infrequent (8, 5%). A total of 83 (53%) patients with reports of myocarditis were hospitalized, for  
278 a median duration of 2.5 days. **Figure 5** summarizes the typical patient management procedure  
279 for a myocarditis following mRNA COVID-19 vaccine.

280

281

282

283

284 **Discussion**

285           In this global pharmacovigilance retrospective observational study, we report here the  
286 largest case series to date on the clinical features of inflammatory heart reactions, myocarditis  
287 and pericarditis, following COVID-19 mRNA vaccine immunization. These cases mostly  
288 required hospitalization and some were life threatening, and occasionally fatal. Fatal cases  
289 occurred in about 1% of the patients, mostly older. Although our analysis cannot assess real  
290 incidence, these inflammatory heart reactions representing 31.8 per 10,000 of COVID-19 mRNA  
291 vaccine reports appeared to be rare. Regarding myocarditis, our global data show that they were  
292 highly likely to be reported in adolescents and young adults below 30 years old. Males has a high  
293 disproportionate reporting risk compared to females.

294           Overall clinical features from these databases are also consistent with the experience  
295 reported by the Israeli investigators. They have identified 110 myocarditis cases amongst their 5  
296 million population who received 2 doses of the tozinameran vaccine.<sup>14</sup> This translates to  
297 approximately 1 in 50,000 vaccine recipients, noting however the rates in young males were 5 to  
298 25 times higher than expected. The investigators also observed a higher rate of incidence  
299 following the second dose, as well as 2 deaths in the cohort which may or may not be causally  
300 related. This overall pattern is consistent with features of traditional viral myocarditis, which  
301 occurs more commonly in younger male patients. Noteworthy, Israel's spontaneous reports are  
302 not transmitted to VigiBase. Israel has been a leader in the current global mass immunization  
303 effort, due to the achievements of the campaign, a larger proportion of young people have been

304 vaccinated compared to other countries using mRNA vaccines. The CDC reported that  
305 myocarditis reactions after vaccination with tozinameran vaccine were reported by adolescents  
306 aged 12–17 years to U.S. vaccine safety monitoring systems.<sup>37</sup>

307 Myocarditis and pericarditis have been previously reported after vaccinations.<sup>8</sup> The most  
308 well studied example is that following smallpox vaccine, which in the relatively healthy U.S.  
309 military personnel had an incidence of myocarditis of 1 in 12,819 individuals.<sup>38</sup> The complication  
310 rate was significantly decreased when the vaccine dose was subsequently reduced, suggesting a  
311 causal relationship, but it featured a live attenuated virus. Inflammatory cardiac reactions after  
312 inactivated virus vaccines such as influenza vaccines are also known to occur, but are generally  
313 considered as rare events, mainly occurring in young adults.<sup>8</sup>

314 Following the widespread adoption of community-based mitigation measures to reduce  
315 the transmission of SARS-CoV-2, the percentage of other respiratory diseases, such as influenza  
316 infection, has declined to historically low levels.<sup>39,40</sup> Therefore, we can hypothesize that the  
317 background risk for myocarditis is probably lower than usual. In this present study, distribution  
318 of myocarditis/pericarditis by sex and age was similar to previous cases described for other  
319 vaccines: mostly young adult males.<sup>8</sup> Potential mechanisms for these observed reactions are  
320 currently unknown, but several hypotheses may be considered. The first is that incidence appears  
321 to be higher in situations related to higher immune reactivity (younger patient population, after  
322 second dose, etc.). This may be related to greater adaptive immune response in younger  
323 individuals, which in turn may lead to greater increases of CD4+ Th17+ cell populations, which  
324 predisposes individuals to developing myocarditis. It will be interesting to see if the recently  
325 reported microRNA diagnostic of Th17 activation in myocarditis is also positive in these  
326 patients.<sup>41</sup> Second is the possibility that mRNA in these vaccines may enhance autoimmunity.<sup>42</sup>  
327 mRNA is known to be a self-adjuvant for innate immune responses, and this may help to explain

328 their immunogenicity, and may also trigger excessive immune responses in some individuals,  
329 especially when there may be presence of a cross-reacting antigen. Optimization of mRNA dose  
330 delivered is needed to elicit appropriate immune response while minimizing undesirable  
331 inflammatory reactions, reassessing the dosing frequency and time interval between doses, as  
332 well as optimization of all ingredients associated with the messenger RNA, in order to achieve  
333 the most beneficial outcome of effective immunization with the least number of adverse effects to  
334 all different population demographics. No previous or concomitant COVID-19 disease before  
335 vaccination were reported in VAERS narratives. Some countries, such as France, recommend for  
336 individuals with previous SARS-CoV-2 infection to delay vaccination from three to six months  
337 after recovery, and to administer only one dose. Finally, with regards to COVID-19, it has been  
338 hypothesized that myocarditis can occur due to direct cell invasion via the spike protein  
339 interacting with the angiotensin-converting enzyme 2 (ACE2), which is widely expressed and  
340 prevalent in cardiomyocytes.<sup>43,44</sup> However, in case of COVID-19 related myocarditis, SARS-  
341 CoV-2 has not been found in cardiomyocytes, but only in the remaining myocardium, thus the  
342 cell injury was thought to be due to the generalized inflammatory response to COVID-19, part of  
343 which is Th1 activation.<sup>45</sup> Hence in COVID-19 mRNA vaccine associated myocarditis, it appears  
344 unlikely that the translation of large amount of SARS-CoV-2 spike proteins through the vaccines  
345 may also engage the ACE2 and related receptors and play a role in reaction onset.

346

347 This retrospective pharmacovigilance analysis has some limitations and strengths.  
348 VigiBase and VAERS are based on spontaneous reports. Anyone can submit a report, including  
349 parents and patients, which are analyzed and documented by national or regional  
350 pharmacovigilance centers. Spontaneous reports will likely feature under-reporting of total real



351 world cases and variable data quality, all of which are inherent to any pharmacovigilance system.

352 <sup>46</sup>

353 For instance, previous prospective study of the incidence of myocarditis/pericarditis following  
354 smallpox and influenza vaccination suggested significant underestimation of true incidence of  
355 these complications with passive surveillance alone.<sup>47</sup> Hence, one major limitation of  
356 spontaneous reporting is that it is not possible to assess incidence of inflammatory heart reactions  
357 following COVID-19 vaccination and total number of cases is highly underestimated. However,  
358 VigiBase, covering more than 90% of the world's population, provides a unique opportunity to  
359 analyze rare adverse events at a global scale. Furthermore, although we cannot eliminate residual  
360 confounders, disproportionality analysis on VigiBase has proven its value in detecting safety  
361 signal or increased risk of events.<sup>34</sup> Our analysis highlights an increased risk of myocarditis  
362 reporting in young males. On one hand, myocarditis has suffered from a notoriety bias in relation  
363 with media communication which has probably increase its reporting in May and June 2021  
364 compared to other vaccine related events. On the other hand, because of an exceptionally high  
365 number of reports with these new COVID-19 mRNA vaccines that are associated to an important  
366 reactogenicity, non-cases reporting may be inflated as well, resulting in an underestimation of  
367 this risk. Finally, it is not likely that study groups in our disproportionality analysis, based on  
368 patient age and sex, may have been imbalanced in relation with these limitations. Sensitivity  
369 analyses showing consistent results strengthen our findings. Hence, data from VigiBase and  
370 VAERS reports should always be interpreted with caution, and consistency across datasets will  
371 be most important for validation of conclusions.<sup>48</sup>

372

373 We first report a global analysis on inflammatory cardiac reactions such as  
374 myocarditis/pericarditis occurring after COVID-19 mRNA vaccine. Compared to hundreds of

375 millions of doses administered worldwide, these complications appeared to be rarely reported,  
376 although most of them required hospitalization. Reporting risk of myocarditis is highly increased  
377 in adolescents or young adults, and in males. Absolute risk may greatly increase with the  
378 achievements of the mass immunization campaign and the enlargement of vaccination to young  
379 adults. COVID-19 mRNA vaccine causality has been established by national authorities; further  
380 data will be needed to analyze this safety signal. Meanwhile, recommendations should be  
381 communicated to manage mass immunization in young adults and children, especially males.  
382 Some authors pledge for adapting the doses and number of doses needed.<sup>49</sup> Benefits of COVID-  
383 19 vaccine still significantly outweigh their risks, including these rare inflammatory heart  
384 complications, given the current prevalence of SARS-CoV-2 infections in the world. As COVID-  
385 19 vaccine administration increases worldwide, clinicians and the public should be aware of the  
386 features of these inflammatory heart reactions, and follow appropriate monitoring and treatment  
387 procedures as with other cases of myocarditis.<sup>50</sup> Maximal monitoring efforts by all relevant  
388 national and international agencies are needed to unlock key parameters to optimize future  
389 generations of vaccine platforms and dissemination to the general public resulting in maximum  
390 benefit potential. Guidelines are needed to take this specific risk into account and to adapt  
391 vaccination (dosage, timing and protocol) for younger people and males. In the future, as newer  
392 formulations are being developed, such as for vaccine boosters, the dose and timing for the at-risk  
393 cohort for cardiac complications should be considered to maximize the benefit to risk ratio.

394

395

396 **Acknowledgments**

397 VigiBase is a fully deidentified database maintained by the Uppsala Monitoring Center (UMC).  
398 The authors are indebted to the National Pharmacovigilance centres that contributed data.  
399 Information from VigiBase comes from a variety of sources, and the probability that the  
400 suspected adverse effect is drug-related is not the same in all cases. The information does not  
401 represent the opinion of the Uppsala Monitoring Center (UMC) or the World Health Organization  
402 and only reflects the authors' opinion.

403 According to VigiBase access rules, no specific ethical approval is needed. VigiBase access is  
404 granted to national and regional pharmacovigilance centers such our teams.

405  
406 **Sources of funding:** This work is supported in part by research grants from the Canadian  
407 Institutes of Health Research, Heart & Stroke Foundation of Canada, Genome Canada, and  
408 University of Ottawa of Heart Institute.

409  
410 **Disclosures:** none

411  
412 **Data availability:** aggregated data of spontaneous reports are available at  
413 <http://www.vigiaccess.org/>.

414  
415 **Author contributions**

416 AB, LC and PL designed the study. AB and LC drafted the article and performed data extraction  
417 and statistical analysis. PL, MAK, TSK, GN, JR, MDD, MBVR, FS, JM and JMT critically  
418 reviewed the article. All the authors approved the final version of the article.

419

420 **REFERENCES**

- 421 1. Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac  
422 injury and repair. *Nat Rev Immunol*. 2015;15:117–129.
- 423 2. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E,  
424 Thiene G, Goodwin J, Gyarfás I, Martin I, Nordet P. Report of the 1995 World Health  
425 Organization/International Society and Federation of Cardiology Task Force on the  
426 Definition and Classification of cardiomyopathies. *Circulation*. 1996;93:841–842.
- 427 3. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, Oliveira MF, Adam RD,  
428 Azimonia N, Menacho K, Chacko L, Brown JT, Patel RK, Shiwani H, Bhuvá A, Augusto  
429 JB, Andiápen M, McKnight A, Noursadeghi M, Pierce I, Evain T, Captur G, Davies RH,  
430 Greenwood JP, Fontana M, Kellman P, Schelbert EB, Treibel TA, Manisty C, Moon JC,  
431 COVIDsortium Investigators. Prospective Case-Control Study of Cardiovascular  
432 Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. *JACC*  
433 *Cardiovasc Imaging*. 2021;S1936-878X(21)00356–9.
- 434 4. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, Jeudy J,  
435 Mattson SE, Law IH, Borchers J, Kovacs R, Kovan J, Rifat SF, Albrecht J, Bento AI,  
436 Albers L, Bernhardt D, Day C, Hecht S, Hipskind A, Mjaanes J, Olson D, Rooks YL,  
437 Somers EC, Tong MS, Wisinski J, Womack J, Esopenko C, Kratochvil CJ, Rink LD, Big  
438 Ten COVID-19 Cardiac Registry Investigators. Prevalence of Clinical and Subclinical  
439 Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the  
440 Big Ten COVID-19 Cardiac Registry. *JAMA Cardiol*. 2021;
- 441 5. Ma R, Wang Q, Meng D, Li K, Zhang Y. Immune checkpoint inhibitors-related myocarditis  
442 in patients with cancer: an analysis of international spontaneous reporting systems. *BMC*  
443 *Cancer*. 2021;21:38.
- 444 6. Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell CL, Boyd SY,  
445 Murphy JG, Swerdlow DL, Collins LC, Riddle JR, Tornberg DN, Grabenstein JD, Engler  
446 RJM, Department of Defense Smallpox Vaccination Clinical Evaluation Team. Incidence  
447 and follow-up of inflammatory cardiac complications after smallpox vaccination. *J Am Coll*  
448 *Cardiol*. 2004;44:201–205.
- 449 7. Griffin JM, Woznica E, Gilotra NA, Nucifora FC. Clozapine-Associated Myocarditis: A  
450 Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to  
451 Conduct a Clozapine Rechallenge. *J Clin Psychopharmacol*. 2021;41:180–185.
- 452 8. Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, Cano MV. Myopericarditis  
453 after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. *Vaccine*.  
454 2021;39:839–845.
- 455 9. Mei R, Raschi E, Forcesi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and  
456 pericarditis after immunization: Gaining insights through the Vaccine Adverse Event  
457 Reporting System. *Int J Cardiol*. 2018;273:183–186.

- 458 10. Casey CG, Iskander JK, Roper MH, Mast EE, Wen X-J, Török TJ, Chapman LE, Swerdlow  
459 DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L,  
460 Vellozzi C, McCauley M, Strikas RA, Mootrey G. Adverse events associated with smallpox  
461 vaccination in the United States, January-October 2003. *JAMA*. 2005;294:2734–2743.
- 462 11. Gatti M, Raschi E, Moretti U, Ardizzoni A, Poluzzi E, Diemberger I. Influenza Vaccination  
463 and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the  
464 Likelihood of Interaction through the Vaccine Adverse Event Reporting System and  
465 VigiBase. *Vaccines*. 2021;9:19.
- 466 12. Watkins K, Griffin G, Septaric K, Simon EL. Myocarditis after BNT162b2 vaccination in a  
467 healthy male. *Am J Emerg Med*. 2021;S0735-6757(21)00536–2.
- 468 13. Purdy A, Ido F, Sterner S, Tesoriero E, Matthews T, Singh A. Myocarditis in COVID-19  
469 presenting with cardiogenic shock: a case series. *Eur Heart J Case Rep*. 2021;5:ytab028.
- 470 14. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrcir  
471 D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT. Myocarditis Following  
472 Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA*  
473 *Cardiol*. 2021;
- 474 15. Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, Couri D, Cereda A,  
475 Procopio A, Cavalotti C, Oliva F, Sanna T, Ciconte VA, Onyango G, Holmes DR, Borgeson  
476 DD. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. *Circulation*.  
477 2021;144:506–508.
- 478 16. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA Vaccines. *Circulation*.  
479 2021;
- 480 17. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J,  
481 Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally  
482 VV, Romero JR, Talbot HK, Lee GM, Daley MF, Oliver SE. Use of mRNA COVID-19  
483 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the  
484 Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morb*  
485 *Mortal Wkly Rep*. 2021;70:977–982.
- 486 18. Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA  
487 vaccines: a biotech and industrial perspective. *NPJ Vaccines*. 2020;5:11.
- 488 19. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,  
489 Roupahel N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,  
490 Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,  
491 Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng  
492 W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and Safety  
493 of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384:403–416.
- 494 20. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc  
495 G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina

- 496 WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan  
497 DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial  
498 Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.*  
499 2020;383:2603–2615.
- 500 21. CDC. COVID Data Tracker [Internet]. Cent. Dis. Control Prev. 2020 [cited 2021 May  
501 20];Available from: <https://covid.cdc.gov/covid-data-tracker>
- 502 22. Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra A-P, Micallef J. Type I  
503 interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy.  
504 *Therapie.* 2021;76:365–367.
- 505 23. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-  
506 19 Vaccines in the US-December 14, 2020-January 18, 2021. *JAMA.* 2021;325:1101–1102.
- 507 24. Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, Cracowski J-L. Association  
508 of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using  
509 the World Health Organization Pharmacovigilance Database. *JAMA Intern Med.* 2021;
- 510 25. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and  
511 COVID-19 vaccination in young men [Internet]. Sci. AAAS. 2021 [cited 2021 Jun  
512 6];Available from: [https://www.sciencemag.org/news/2021/06/israel-reports-link-between-](https://www.sciencemag.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination)  
513 [rare-cases-heart-inflammation-and-covid-19-vaccination](https://www.sciencemag.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination)
- 514 26. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and  
515 Pericarditis After Vaccination for COVID-19. *JAMA.* 2021;
- 516 27. COVID-19 vaccine benefits still outweigh risks, despite possible rare heart complications  
517 [Internet]. Am. Heart Assoc. [cited 2021 May 28];Available from:  
518 [https://newsroom.heart.org/news/covid-19-vaccine-benefits-still-outweigh-risks-despite-](https://newsroom.heart.org/news/covid-19-vaccine-benefits-still-outweigh-risks-despite-possible-rare-heart-complications)  
519 [possible-rare-heart-complications](https://newsroom.heart.org/news/covid-19-vaccine-benefits-still-outweigh-risks-despite-possible-rare-heart-complications)
- 520 28. PINHO AC. Comirnaty and Spikevax: possible link to very rare cases of myocarditis  
521 pericarditis [Internet]. Eur. Med. Agency. 2021 [cited 2021 Aug 11];Available from:  
522 [https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-](https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis)  
523 [myocarditis-pericarditis](https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis)
- 524 29. Commissioner O of the. Coronavirus (COVID-19) Update: June 25, 2021 [Internet]. FDA.  
525 2021 [cited 2021 Aug 11];Available from: [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021)  
526 [announcements/coronavirus-covid-19-update-june-25-2021](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021)
- 527 30. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. *Drug Inf J.*  
528 2008;42:409–419.
- 529 31. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine  
530 Adverse Event Reporting System (VAERS). *Vaccine.* 2015;33:4398–4405.

- 531 32. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP,  
532 Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization:  
533 Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. *Morb*  
534 *Mortal Wkly Rep Surveill Summ Wash DC 2002*. 2003;52:1–24.
- 535 33. Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient  
536 consent in clinical research. *Anaesth Crit Care Pain Med*. 2020;39:883–885.
- 537 34. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the  
538 disproportionality analysis for identification of adverse drug reactions in a  
539 pharmacovigilance database. *Br J Clin Pharmacol*. 2011;72:905–908.
- 540 35. Faillie J-L. Case-non-case studies: Principle, methods, bias and interpretation. *Therapie*.  
541 2019;74:225–232.
- 542 36. Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski J-L. Adverse drug  
543 reaction risks obtained from meta-analyses and pharmacovigilance disproportionality  
544 analyses are correlated in most cases. *J Clin Epidemiol*. 2021;134:14–21.
- 545 37. Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, Su JR, Licata C,  
546 Rosenblum HG, Myers TR, Shimabukuro TT, Shay DK. COVID-19 Vaccine Safety in  
547 Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. *MMWR*  
548 *Morb Mortal Wkly Rep*. 2021;70:1053–1058.
- 549 38. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, Gray GC, Ostroff S,  
550 Eckart RE, Hospenthal DR, Gibson RL, Grabenstein JD, Arness MK, Tornberg DN,  
551 Department of Defense Smallpox Vaccination Clinical Evaluation Team. Myopericarditis  
552 following smallpox vaccination among vaccinia-naive US military personnel. *JAMA*.  
553 2003;289:3283–3289.
- 554 39. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen C,  
555 Fry AM. Decreased Influenza Activity During the COVID-19 Pandemic - United States,  
556 Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:1305–  
557 1309.
- 558 40. Jones N. How COVID-19 is changing the cold and flu season. *Nature*. 2020;588:388–390.
- 559 41. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, Jiménez-Borreguero LJ, Matesanz-  
560 Marín A, Relañó M, Jiménez-Alejandre R, Linillos-Pradillo B, Tsilingiri K, Martín-  
561 Mariscal ML, Alonso-Herranz L, Moreno G, Martín-Asenjo R, García-Guimaraes MM,  
562 Bruno KA, Dauden E, González-Álvaro I, Villar-Guimerans LM, Martínez-León A,  
563 Salvador-Garicano AM, Michelhaugh SA, Ibrahim NE, Januzzi JL, Kottwitz J, Iliceto S,  
564 Plebani M, Basso C, Baritussio A, Seguso M, Marcolongo R, Ricote M, Fairweather D,  
565 Bueno H, Fernández-Friera L, Alfonso F, Caforio ALP, Pascual-Figal DA, Heidecker B,  
566 Lüscher TF, Das S, Fuster V, Ibáñez B, Sánchez-Madrid F, Martín P. A Novel Circulating  
567 MicroRNA for the Detection of Acute Myocarditis. *N Engl J Med*. 2021;384:2014–2027.

- 568 42. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the  
569 Cardiovascular System. *Circulation*. 2020;142:68–78.
- 570 43. Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, Cooper LT, Chahal  
571 CAA. Recognizing COVID-19-related myocarditis: The possible pathophysiology and  
572 proposed guideline for diagnosis and management. *Heart Rhythm*. 2020;17:1463–1471.
- 573 44. Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression  
574 profile of ACE2 in human tissues. *Mol Syst Biol*. 2020;16:e9610.
- 575 45. Mele D, Flamigni F, Rapezzi C, Ferrari R. Myocarditis in COVID-19 patients: current  
576 problems. *Intern Emerg Med*. 2021;16:1123–1129.
- 577 46. Navar AM, McNally E, Yancy CW, O’Gara PT, Bonow RO. Temporal Associations  
578 Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The  
579 Vaccine Safety Surveillance System Is Working. *JAMA Cardiol*. 2021;
- 580 47. Engler RJM, Nelson MR, Collins LC, Spooner C, Hemann BA, Gibbs BT, Atwood JE,  
581 Howard RS, Chang AS, Cruser DL, Gates DG, Vernalis MN, Lengkeek MS, McClenathan  
582 BM, Jaffe AS, Cooper LT, Black S, Carlson C, Wilson C, Davis RL. A prospective study of  
583 the incidence of myocarditis/pericarditis and new onset cardiac symptoms following  
584 smallpox and influenza vaccination. *PloS One*. 2015;10:e0118283.
- 585 48. Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C,  
586 Edwards KM, Klein J, Klein NP, LaRussa P, Sparks R, Jakob K. Causality assessment of  
587 adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).  
588 *Vaccine*. 2012;30:7253–7259.
- 589 49. Harlan M. Krumholz MD. Myocarditis After mRNA COVID-19 Vaccine. *NEJM J Watch*  
590 [Internet]. 2021 [cited 2021 Aug 12];2021. Available from:  
591 <https://www.jwatch.org/NA53825/2021/07/20/myocarditis-after-mrna-covid-19-vaccine>
- 592 50. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG,  
593 Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss H-P, Tschöpe C,  
594 Cooper LT, Camici PG. Management of Acute Myocarditis and Chronic Inflammatory  
595 Cardiomyopathy: An Expert Consensus Document. *Circ Heart Fail*. 2020;13:e007405.

596



597 **FIGURE TITLES AND LEGENDS**

598

599 **Figure 1. Clinical and demographic features concerning inflammatory heart reaction after**  
600 **mRNA COVID-19 vaccines**

601 The data shown refer to VigiBase data.

602 **(A)** Sex distribution according to reaction type (myocarditis and pericarditis). **(B)** Reaction type  
603 (Myocarditis or Pericarditis) distribution according to age. Myocarditis presented most frequently  
604 in young people of 18-29 years old, whereas pericarditis presented most frequently in people over  
605 65 years old. **(C)** Sex distribution according to reaction type and age.

606

607 **Figure 2. Reported cases of myocarditis and number of people vaccinated among 12-17 and**  
608 **18-29 year old in the U.S..**

609 Myocarditis originating from the U.S. were mainly reported after May 2021.

610

611 **Figure 3. Time to onset and main symptoms reported by type of reaction**

612 Time to onset was earlier for myocarditis. Most frequent symptoms reported were chest pain,  
613 elevated troponin and systemic reactogenicity.

614 SOB, shortness of breath

615

616 **Figure 4. Comparison of reports of inflammatory cardiac disorders in COVID-19 mRNA**  
617 **vaccine recipients according sex and age within the WHO global safety database**

618  
619 ROR, Reporting odds-ratio; 95% CI, 95% confidence interval.  
620 Case–non-case approach is similar to case–control method but for the purposes of  
621 pharmacovigilance studies. Disproportionality in adverse drug reaction reporting between groups  
622 is expressed using reporting odds ratios (ROR) and their 95% confidence interval (95% CI). ROR  
623 is a ratio similar in concept to the odds ratio in case-control studies and corresponds to the  
624 exposure odds among reported cases of inflammatory cardiac disorders over the exposure odds  
625 among reported non-cases. An ROR over 1.0 suggests that inflammatory cardiac disorders are  
626 more frequently reported in COVID-19 mRNA vaccine recipients specific group compared with  
627 control group. We performed the main analysis and a secondary analysis stratified to age groups.

628 \* Inflammatory cardiac disorders cases were individual case safety reports containing the terms  
629 myocarditis or pericarditis as a reported preferred term according to the Medical Dictionary for  
630 Regulatory Activities (MedDRA, <https://www.meddra.org/>). Cases of myopericarditis have been  
631 considered as myocarditis.

632 \*\* Non cases were reports containing any other reaction.

633

634 **Figure 5. Management of a typical vaccine related myocarditis patient**

635 The typical journey of patient experienced a myocarditis following an mRNACOVID-19 vaccine  
636 is described. Starting at day 0 after receiving 1<sup>st</sup> or 2<sup>nd</sup> dose of vaccine. Appearance of systemic  
637 reactogenicity symptoms at day 1, followed by chest pain and shortness of breath (SOB) at day 3,  
638 leading to consultation at the Emergency Room (ER), and hospitalization for a median of 2 days.

639 SOB, shortness of breath; EKG, electrocardiogram; CT, computed tomography; NSAID, non-  
640 steroidal anti-inflammatory drug.

641

642 **Supplemental Figure 1. Date of reporting and reaction of inflammatory heart reaction cases**  
643 **in VigiBase.**

644

**Table 1. Characteristics of acute inflammatory heart cases reported with COVID-19 mRNA vaccines within the WHO global safety database**

Reporting characteristics	Tozinameran vaccine (n=1655)	Elasomeran vaccine (n=622)	Overall (n=2277)
Continent of reporting			
- North America	942 (56.9%)	502 (80.7%)	1444 (63.4%)
- Europa	676 (40.8%)	120 (19.3%)	796 (35.0%)
- Oceania	31 (1.9%)	-	31 (1.4%)
- Latin America	5 (0.3%)	-	5 (0.2%)
- Africa	1 (0.1%)	-	1 (0.1%)
Type of reporter			
- Physician	383 (23.1%)	75 (12.1%)	458 (20.1%)
- Pharmacist	35 (2.1%)	9 (1.4%)	44 (1.9%)
- Other health professional	46 (2.8%)	2 (0.3%)	48 (2.1%)
- Consumer	234 (14.1%)	34 (5.5%)	268 (11.8%)
- Unknown	957 (57.8%)	502 (80.7%)	1459 (64.1%)
Sex – male (%)	1108 (66.9%)	447 (71.9%)	1555 (68.3%)
Age – years	33 (19-55)	31 (22-52)	33 (21-54)
Age – ranges			
- 12 - 17 years	291 (17.6%)	3 (0.5%)	294 (12.9%)
- 18 - 29 years	425 (25.7%)	279 (44.9%)	704 (30.9%)
- 30 – 39 years	234 (14.1%)	103 (16.6%)	337 (14.8%)
- 40 - 49 years	171 (10.3%)	64 (10.3%)	235 (10.3%)
- 50 - 59 years	173 (10.5%)	50 (8.0%)	223 (9.8%)
- 60 - 64 years	74 (4.5%)	30 (4.8%)	104 (4.6%)
- 65+	240 (14.5%)	77 (12.4%)	317 (13.9%)
- Unknown	47 (2.8%)	16 (2.6%)	63 (2.8%)
Type of heart inflammatory injury			
• Myocarditis	905 (54.7%)	336 (54.0%)	1241 (54.5%)
- Including requiring hospitalization	573 (63.3%)	223 (66.4%)	796 (64.1%)
- Including life threatening condition	150 (16.6%)	69 (20.5%)	219 (17.6%)
- Including fatal outcome	11 (1.2%)	4 (1.2%)	15 (1.2%)
• Pericarditis	621 (37.5%)	230 (37.0%)	851 (37.4%)
- Including requiring hospitalization	287 (46.2%)	104 (45.2%)	391 (45.9%)
- Including life threatening condition	59 (9.5%)	42 (18.3%)	101 (11.9%)
- Including fatal outcome	3 (0.5%)	2 (0.9%)	5 (0.6%)
• Myopericarditis	115 (6.9%)	52 (8.4%)	167 (7.3%)
- Including requiring hospitalization	71 (61.7%)	38 (73.1%)	109 (65.3%)
- Including life threatening condition	21 (18.3%)	8 (15.4%)	29 (17.4%)
- Including fatal outcome	1 (0.9%)	1 (1.9%)	2 (1.2%)
• Pleuropericarditis	14 (0.8%)	4 (0.6%)	18 (0.8%)
- Including requiring hospitalization	10 (71.4%)	2 (50.0%)	12 (66.7%)
- Including life threatening condition	2 (14.3%)	1 (25.0%)	3 (16.7%)
- Including fatal outcome	-	-	-
Time to onset – days			
• Myocarditis	3 [2-7]	3 [2-4]	3 [2-6]
• Pericarditis	8 [3-20]	10 [4-33]	8 [3-21]
• Myopericarditis	4 [2-14]	3 [2-12]	4 [2-14]
• Pleuropericarditis	8 [3-23]	6 [2-13]	7 [3-19]
Cases with other suspected reported drug***	155 (9.4%)	45 (7.2%)	200 (8.7%)

Month of reporting			
- January	21 (1.3%)	-	21 (0.9%)
- February	63 (3.8%)	33 (5.3%)	96 (4.2%)
- March	79 (4.8%)	27 (4.3%)	106 (4.7%)
- April	58 (3.5%)	22 (3.5%)	80 (3.5%)
- May	369 (22.3%)	118 (19.0%)	487 (21.4%)
- June	1065 (64.4%)	422 (67.8%)	1487 (65.3%)

Data are presented as N (%) or median (IQR)

**Table 2. Characteristics of acute inflammatory heart cases reported with COVID-19 mRNA vaccines within the VAERS classified by the type of reaction**

<b>Reporting characteristics (%) or median [IR]</b>	<b>Myocarditis (n=157)</b>	<b>Pericarditis (n=122)</b>	<b>Overall (n=279)</b>
Vaccine type			
- Tozinameran	89 (57%)	73 (60%)	117 (42%)
- Elasmomeran	68 (43%)	49 (40%)	162 (58%)
Sex			
- Male	114 (73%)	68 (55%)	182 (65%)
- Female	38 (24%)	52 (43%)	90 (32%)
- Unknown	5 (3%)	2 (2%)	7 (3%)
Age – ranges			
- 12 - 17 years	7 (4%)	0 (0%)	7 (3%)
- 18 - 29 years	75 (48%)	17 (14%)	92 (33%)
- 30 – 39 years	28 (18%)	22 (18%)	50 (18%)
- 40 - 49 years	24 (15%)	11 (9%)	35 (13%)
- 50 - 59 years	8 (5%)	21 (17%)	29 (10%)
- 60 - 64 years	3 (2%)	7 (6%)	10 (4%)
- 65+	7 (4%)	38 (31%)	45 (16%)
- Unknown	5 (3%)	6 (5%)	11 (4%)
COVID-19 prior to vaccination	10 (6%)	8 (7%)	18 (6%)
After 1 <sup>st</sup> dose	22 (14%)	29 (24%)	52 (19%)
- Covid prior vaccination			13 (25%)
- No Covid prior vaccination			15 (29%)
- Unknown			24 (46%)
After 2 <sup>nd</sup> dose	56 (36%)	30 (25%)	87 (31%)
- Covid prior vaccination			2 (2%)
- No Covid prior vaccination			34 (39%)
- Unknown			51 (59%)
After unspecified dose	79 (50%)	63 (51%)	140 (50%)
- Covid prior vaccination			3 (2%)
- No Covid prior vaccination			12 (9%)
- Unknown			125 (89%)
Onset of the first symptoms – days	3 [2-4]	3 [2-9]	3 [2-5]
Symptoms			
- Systemic reactogenicity signs	70 (45%)	37 (30%)	108 (39%)
- Chest Pain	107 (68%)	79 (65%)	187 (67%)
- Shortness of breath	25 (16%)	31 (25%)	57 (20%)
EKG			
- Abnormal	67 (43%)	41 (34%)	110 (39%)
- ST elevation	41 (26%)	13 (11%)	54 (19%)
- Supraventricular arrhythmia	3 (2%)	13 (11%)	16 (6%)
Elevated Troponin	99 (63%)	19 (16%)	120 (43%)
Trans Thoracic Echocardiography			
- Normal	22 (14%)	7 (6%)	29 (10%)
- Decreased LVEF	14 (9%)	4 (3%)	19 (7%)
CMR consistent with diagnosis	29 (18%)	1 (1%)	30 (11%)
Complications			
- CS or AHF	9 (6%)	1 (1%)	10 (4%)


- Cardiac arrest	2 (1%)	0 (0%)	2 (1%)
- Tamponade	0 (0%)	8 (7%)	8 (3%)
Treatment			
- NSAID	23 (15%)	0 (0%)	43 (15%)
- Colchicine	22 (14%)	22 (18%)	44 (16%)
- Corticosteroids	8 (5%)	3 (2%)	12 (4%)
Hospitalization	83 (53%)	36 (30%)	121 (43%)
Length of hospital stay – days	2.5 [1-3]	2 [1-4]	2 [1-3]

Data are presented as N (%) or median (IQR)


Data extracted from VAERS up to May 21<sup>st</sup> 2021.

AHF, Acute Heart Failure; CMR, Cardiac magnetic resonance ; CS, Cardiogenic Shock; EKG, electrocardiogram; LVEF, Left ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drug.

**A**



**B**



**C**




Figure 1.








Figure 2.



**B Myocarditis main symptoms**



**C Pericarditis main symptoms**




Figure 3.

A

	Myocarditis cases*	Non cases**	ROR (95% CI)
<b>Myocarditis – Overall analysis</b>			
Male	1,049	171,495	9.4 (8.3-10.6)
Female	322	493,696	1 (Reference)
12-17 years	249	11,265	22.3 (19.2-25.9)
18-29 year	557	84,576	6.6 (5.9-7.5)
≥ 30 years	565	569,350	1 (Reference)
<b>Myocarditis – Analysis according to patient age</b>			
<i>Male</i>			
12-17 years	225	4,940	18.5 (15.6-21.9)
18-29 year	464	20,111	9.4 (8.2-10.8)
≥ 30 years	360	146,444	1 (Reference)
<i>Female</i>			
12-17 years	24	6,325	7.8 (5.1-12.0)
18-29 years	93	64,465	3.0 (2.3-3.8)
≥ 30 years	205	422,906	1 (Reference)
<b>Myocarditis – Analysis according to patient sex</b>			
<i>12-17 years</i>			
Male	225	4,940	12.0 (7.9-18.3)
Female	24	6,325	1 (Reference)
<i>18-29 years</i>			
Male	464	20,111	16.0 (12.8-20.0)
Female	93	64,465	1 (Reference)
<i>≥ 30 years</i>			
Male	360	146,444	5.1 (4.3-6.0)
Female	205	422,906	1 (Reference)




Figure 4.A

B

	Pericarditis cases*	Non cases**	ROR (95% CI)
<b>Pericarditis – Overall analysis</b>			
Male	459	172,085	3.7 (3.2-4.2)
Female	360	493,658	1 (Reference)
<b>Pericarditis – Analysis according to patient age</b>			
<i>Male</i>			
12-17 years	41	5,124	3.7 (2.6-5.1)
18-29 year	104	20,471	2.4 (1.9-3.0)
≥ 30 years	314	146,490	1 (Reference)
<i>Female</i>			
12-17 years	4	6,345	0.8 (0.3-2.3)
18-29 years	41	64,517	0.9 (0.6-1.2)
≥ 30 years	315	422,796	1 (Reference)
<b>Pericarditis – Analysis according to patient sex</b>			
<i>12-17 years</i>			
Male	41	5,124	12.7 (4.5-35.5)
Female	4	6,345	1 (Reference)
<i>18-29 years</i>			
Male	104	20,471	8.0 (5.6-11.5)
Female	41	64,517	1 (Reference)
<i>≥ 30 years</i>			
Male	314	146,490	2.9 (2.5-3.4)
Female	315	422,796	1 (Reference)




Figure 4.B

# Management of a typical vaccine related myocarditis patient




Figure 5.